CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Abametapir Lotion 0.74% w/w +3 moredrug
Likely dose
Abametapir Lotion 0.74% w/w 0.2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02061813
NCT02061813Phase 1Completed
CompareCT.gov

A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Abametapir Lotion in Healthy Volunteers, Using a Cumulative Irritant Patch Test Design

Dr. Reddy's Laboratories Limited·interventional·Posted Feb 13, 2014·Updated Jul 26, 2021

In Brief

A Phase 1 clinical trial evaluating Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, and 2 other interventions for Head Lice. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of the study is to determine the irritation potential of repeat applications of abametapir lotion on normal skin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead Lice
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 13, 2014
Enrollment StartJan 1, 2014
Primary CompletionJan 1, 2014
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 12.4 years ago

Interventions

Abametapir Lotion 0.74% w/wdrug

applied 0.2 mL topically under occlusive condition

Sodium Lauryl Sulfatedrug

Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.

Saline 0.9%drug

A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control

Placebodrug